Royalty Report: Drugs, Biotechnology, nucleic acid – Collection: 27466


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Biotechnology
  • nucleic acid
  • ribonucleic acid
  • Medical
  • Genome

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 27466

License Grant
The Parties desire to settle their disputes regarding the Action and the Disputed Technology on the terms and conditions set forth. The Parties do not intend to release any other claims unless specifically set forth.  The Parties agree that 2 of the parties are still bound by the Settlement Agreement of February 26, 1996 (the 1996 Settlement Agreement), which unless specifically modified herein, remains in full force and effect.  One party hereby agrees to dismiss with prejudice its claims in the Action. The other two parties hereby agree to dismiss with prejudice their counterclaims in the Action.
License Property
This litigation, including all claims and counter-claims contained therein, is referred to herein as 'the Action.' More specifically, the dispute between the parties concerns the inventorship and ownership of the currently issued claims of the U.S. Patent Nos. 6,093,302 (the '`302 Patent') and 6,280,595 (the '`595 Patent') and of foreign equivalents of said claims (collectively the 'Disputed Technology').

IPSCIO Record ID: 27848

License Grant
The Parties desire to settle their disputes regarding U.S. Patent Nos. 6,093,302  and 6,280,595.
License Property
'Products 'shall mean chips, reagents, instruments, and software, the use of which would infringe or contribute to the infringement of one or more claims of the Patents.

This settlement agreement concerns the inventorship and ownership of the U.S. Patent Nos. 6,093,302  and 6,280,595 and of foreign equivalents.

IPSCIO Record ID: 204530

License Grant
The Licensee entered into a settlement agreement with the Licensor to settle all pending litigation between the parties. Patents related to genetic information had been in dispute.
License Property
The Licensor specializes in molecular diagnostics.
Field of Use
The Licensee is a genetic information company.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.